Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 6/20 | 0.61 |
| ▸ | WEE1 | P30291 | 4/20 | 0.61 |
| ▸ | CDK9 | P50750 | 3/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.61 |
| ▸ | AURKA | O14965 | 2/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.61 |
| ▸ | JAK2 | O60674 | 2/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.61 |
| ▸ | PAK4 | O96013 | 2/20 | 0.61 |
| ▸ | LCK | P06239 | 2/20 | 0.61 |
| ▸ | FYN | P06241 | 2/20 | 0.61 |
| ▸ | CSF1R | P07333 | 2/20 | 0.61 |
| ▸ | RET | P07949 | 2/20 | 0.61 |
| ▸ | IGF1R | P08069 | 2/20 | 0.61 |
| ▸ | MET | P08581 | 2/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.61 |
| ▸ | PRKACA | P17612 | 2/20 | 0.61 |
| ▸ | FLT1 | P17948 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112988 | 0.92 | PDGFRA (0.61) | ALKWEE1CDK9NTRK1PDGFRA | |
| SCHEMBL3112708 | 0.84 | ALK (0.63) | ALKWEE1CDK9NTRK1PDGFRA | |
| SCHEMBL3114861 | 0.81 | ALK (0.55) | ALKWEE1CDK9NTRK1PDGFRA | |
| SCHEMBL13268184 | 0.80 | ALK (0.60) | ALKWEE1CDK9NTRK1PDGFRA | |
| SCHEMBL12854603 | 0.79 | ALK (0.59) | ALKWEE1CDK9NTRK1PDGFRA | |
| SCHEMBL12854601 | 0.79 | ALK (0.63) | ALKWEE1CDK9NTRK1PDGFRA | |
| SCHEMBL1474190 | 0.78 | INSR (0.47) | ALKMETBRD4 | |
| SCHEMBL1474631 | 0.78 | INSR (0.48) | ALKCDK9NTRK1AURKADAPK3 | |
| SCHEMBL1474365 | 0.78 | CCNT1 (0.58) | ALKCDK9NTRK1AURKAMET | |
| SCHEMBL1473841 | 0.77 | ALK (0.56) | ALKCDK9NTRK1PDGFRAAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | ALK 3241/4885WEE1 342/4885CDK9 21/4885 |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | ALK 3686/4885WEE1 236/4885CDK9 25/4885 |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | ALK 3241/4885WEE1 342/4885CDK9 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.